Zasocitinib is effective in improving skin clearance for PsO patients in hard-to-treat areas with once-daily treatment

An AI-guided network analysis of genomic data (left) highlights two protein targets, including the oxytocin receptor, identified through Biohub’s CRISPR screen in primary human skin cells (right). Image by Zhao, C., Shih, M., Ahmed, S. et al. Nat Commun (2026). Researchers have combined genome-wide CRISPR screening with artificial intelligence to identify two unexpected therapeutic targets for psoriasis, opening a possible path toward topical treatments that avoid systemic im

GLP-1 receptor agonists may have potential applications as adjunct therapy for PsO, AD, HS, chronic wounds, and other skin conditions.

Trust levels regarding topical therapy were higher among AD patients than PsO patients

A text message intervention system improved cardiovascular risk behaviours and patient confidence managing their health in adult psoriasis patients

All patients self-identified as non-White and nearly 69% of treated subjects had objectively measured Fitzpatrick skin types IV through VI The IL-23 inhibitor guselkumab demonstrated efficacy out to 100 weeks in the treatment of psoriasis across a spectrum of skin types, according to poster research presented at the 2026 annual meeting of the American Academy of Dermatology (AAD) in Denver. A full report will be published in the June 2026 issue of The Chronicle of Skin & Alle

Photo by G.steph.rocket via Wikimedia Commons Study shows positive effects of diet on normal-weight patients with psoriasis A healthy diet is widely considered to play a role in improving psoriasis symptoms, supporting the anti-inflammatory benefits of weight loss in overweight or obese psoriasis patients, but there are benefits independent of weight loss seen in patients of all body weights. That’s according to Dr. Javier Perez-Bootelloof, Hospital Universitario Ramón y Caja

Concomitant ixekizumab and tirzepatide improved skin clearance and reductions in weight in patients with moderate-to-severe psoriasis